Veracyte Announces Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
Veracyte (VCYT) Halted on LUDP
November 7, 2017 9:31 AM ESTVeracyte (NASDAQ: VCYT) Halted on LUDP
... MoreVeracyte, Inc (VCYT) PT Lowered to $9 at Leerink Partners
November 7, 2017 8:10 AM ESTLeerink Partners lowered its price target on Veracyte, Inc (NASDAQ: VCYT) to $9.00 (from $12.00) while maintaining an Outperform rating following lower than expected Q3 revenue and guidance.
Analyst Puneet Souda is keeping the Outperform rating on the view that the company offers differentiated negative... More
Veracyte (VCYT) Tops Q3 EPS by 2c
November 6, 2017 4:19 PM ESTVeracyte (NASDAQ: VCYT) reported Q3 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $17.5 million versus the consensus estimate of $19.55 million.
We delivered a solid performance this quarter in which we grew our genomic test... More
